United States - English - NLM (National Library of Medicine)

major pharmaceuticals - rivastigmine tartrate (unii: 9iy2357jpe) (rivastigmine - unii:pki06m3iw0) - rivastigmine tartrate capsules are indicated for the treatment of mild-to-moderate dementia of the alzheimer's type (ad). rivastigmine tartrate capsules are indicated for the treatment of mild-to-moderate dementia associated with parkinson’s disease (pd). rivastigmine tartrate capsules are contraindicated in patients with: isolated cases of generalized skin reactions have been described in postmarketing experience [see adverse reactions (6.2)] . risk summary there are no adequate data on the developmental risks associated with the use of rivastigmine tartrate capsules in pregnant women. in animals, no adverse effects on embryo-fetal development were observed at oral doses 2 to 4 times the maximum recommended human dose (mrhd) (see data). the background risk of major birth defects and miscarriage for the indicated population is unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respective

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - rivastigmine 18 mg - transdermal patch - 9,5 mg/24 h - rivastigmine 18 mg - rivastigmine

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - rivastigmine 18 mg - transdermal patch - 4,6 mg/24 h - rivastigmine 18 mg - rivastigmine

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - rivastigmine 27 mg - transdermal patch - 13,3 mg/24 h - rivastigmine 27 mg - rivastigmine

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

viatris gx bv-srl - rivastigmine 6,9 mg - transdermal patch - 4,6 mg/24 h - rivastigmine 6.9 mg - rivastigmine

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

viatris gx bv-srl - rivastigmine 13,8 mg - transdermal patch - 9,5 mg/24 h - rivastigmine 13.8 mg - rivastigmine

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

teva pharma belgium sa-nv - rivastigmine 9 mg - transdermal patch - 4,6 mg/24 h - rivastigmine 9 mg - rivastigmine

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

teva pharma belgium sa-nv - rivastigmine 18 mg - transdermal patch - 9,5 mg/24 h - rivastigmine 18 mg - rivastigmine

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

teva pharma belgium sa-nv - rivastigmine 27 mg - transdermal patch - 13,3 mg/24 h - rivastigmine 27 mg - rivastigmine

United States - English - NLM (National Library of Medicine)

breckenridge pharmaceutical, inc. - rivastigmine (unii: pki06m3iw0) (rivastigmine - unii:pki06m3iw0) - rivastigmine transdermal system is indicated for the treatment of dementia of the alzheimer's type (ad). efficacy has been demonstrated in patients with mild, moderate, and severe alzheimer's disease. rivastigmine transdermal system is indicated for the treatment of mild-to-moderate dementia associated with parkinson's disease (pdd). rivastigmine transdermal system is contraindicated in patients with: - known hypersensitivity to rivastigmine, other carbamate derivatives, or other components of the formulation [see description (11)] . - previous history of application site reactions with rivastigmine transdermal patch suggestive of allergic contact dermatitis [see warnings and precautions (5.3)] . isolated cases of generalized skin reactions have been described in postmarketing experience [see adverse reactions (6.2)] . risk summary there are no adequate data on the developmental risks associated with the use of rivastigmine transdermal system in pregnant women. in animals, no adverse effects on embryo-fetal d